Therapy News and Research

RSS

MSF, DNDi analysis shows increased investment in NTDs but low number of new therapy approvals

"Over the past decade, neglected diseases have attracted increased attention and larger investments in research," but "a new analysis by Medecins Sans Frontieres (MSF) and the Drugs for Neglected Diseases Initiative (DNDi) finds that the rate of approvals for new compounds over the past decade is roughly the same as it was during the previous two-and-a-half decades, when the diseases received little attention," Nature Medicine reports.

10 Jan 2013

New publication focuses on microbiome research in environmental, agricultural and biomedical areas

Two prominent microbiologists have launched a new peer-reviewed publication focusing on microbiome research in environmental, agricultural, and biomedical areas. Eric Wommack, from the University of Delaware's College of Earth, Ocean and Environment and Jacques Ravel, from the University of Maryland School of Medicine's Institute for Genome Sciences are the Editors-in-Chief of Microbiome, a BioMed Central (BMC) publication, which launched its first issue this week.

9 Jan 2013

Leptin hormone also regulates airway diameter

A new study led by Columbia University Medical Center (CUMC) researchers has found that leptin, a hormone that plays a key role in energy metabolism, fertility, and bone mass, also regulates airway diameter.

9 Jan 2013

Concern regarding cefixime failure rate in gonorrhea patients

Results from a Canadian study add to those of prior studies suggesting that resistance of Neisseria gonorrhoeae to the cephalosporin antibiotic cefixime is increasing worldwide.

9 Jan 2013

Surgical methods outperform radiation therapy in prostate cancer

A surgical method for treating localized prostate cancer may be a better option for patients than radiation therapy, show findings from a cost-effectiveness analysis.

9 Jan 2013

Oxaliplatin and bevacizumab disappoint for rectal cancer

The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results.

9 Jan 2013

CTI initiates enrollment in pacritinib Phase 3 trial for myelofibrosis

Cell Therapeutics, Inc. (CTI) today announced that the Company has initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor, which is being evaluated for the treatment of patients with myelofibrosis.

9 Jan 2013

Nutrisystem reduces arterial stiffness associated with menopause and obesity

Arturo Figueroa, a researcher in the Florida State University College of Human Sciences, has confirmed with a team of researchers that Nutrisystem, with or without low intense resistance exercise, improves arterial function in obese, postmenopausal women.

9 Jan 2013

Combination of pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer

A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine.

9 Jan 2013

Sublingual immunotherapy can effectively treat peanut allergy

Peanuts are one of the most common triggers of severe food-induced allergic reactions, which can be fatal, and the prevalence of peanut allergy is increasing. However, there is currently no clinical treatment available for peanut allergy other than strict dietary elimination and, in cases of accidental ingestion, injections of epinephrine.

9 Jan 2013

Orexigen reports progress with FDA on faster path to Contrave NDA resubmission

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced progress with the United States Food and Drug Administration (FDA) on a faster path to resubmission of the Contrave (naltrexone SR / bupropion SR) New Drug Application (NDA).

9 Jan 2013

ISCT selects Elsevier to publish Cytotherapy

Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce that the International Society for Cellular Therapy (ISCT) has selected Elsevier to publish Cytotherapy: The Journal of Cell Therapy effective January 2013.

8 Jan 2013

Psychologic treatment has long-term benefits for bipolar patients

Psychoeducation and cognitive behavioral therapy combined with pharmacologic treatment provides significant long-term benefits for patients with refractory bipolar disorder, researchers report.

8 Jan 2013

Arterial elasticity link to lung function

People with reduced arterial elasticity may have impaired lung function, and vice versa, say US researchers.

8 Jan 2013

Chronic neck pain patients show respiratory weakness

Chronic neck pain appears to be associated with impaired respiratory function due to weakness of the respiratory muscles, study findings indicate.

8 Jan 2013

Adolescents may lose hepatitis B virus protection despite vaccination as infants

New research reveals that a significant number of adolescents lose their protection from hepatitis B virus (HBV) infection, despite having received a complete vaccination series as infants. Results in the January 2013 issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, suggest teens with high-risk mothers (those positive for HBeAg) and teens whose immune system fails to remember a previous viral exposure (immunological memory) are behind HBV reinfection.

8 Jan 2013

Esperion reports positive results from ETC-1002 Phase 2 clinical trial on type 2 diabetes

Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.

8 Jan 2013

Thoratec to start REVIVE-IT study using HeartMate II Left Ventricular Assist System

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that the U.S. Food and Drug Administration has granted an Investigational Device Exemption to commence the REVIVE-IT study utilizing the HeartMate II Left Ventricular Assist System.

8 Jan 2013

FDA approves use of iCAD's PowerLook AMP with Philips MicroDose Digital Mammography System

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced approval by the U.S. Food and Drug Administration for use of the company's next generation mammography computer-aided detection platform, PowerLook Advanced Mammography Platform, with Digital CAD for Philips' MicroDose Full-Field Digital Mammography System.

8 Jan 2013